Generic Combivir is used for treating HIV infection in combination with other medicines.
Other names for this medication:
Also known as: Lamivudine\Zidovudine.
Generic Combivir is an antiviral combination. Lamivudine and Zidovudine are both nucleoside analogues that work together to slow the growth of HIV by blocking an enzyme needed by the virus to reproduce.
Generic Name of Generic Combivir is Lamivudine plus Zidovudine.
Combivir is also known as Lamivudine, Zidovudine, Duovir.
Brand name of Generic Combivir is Combivir.
Generic Combivir is available in tablets which should be taken orally.
Take Generic Combivir with or without food.
Continue to use Generic Combivir even if you feel well. Do not miss any doses.
Take Generic Combivir at the same time each day.
Do not stop taking it suddenly.
If you overdose Generic Combivir and you don't feel good you should visit your doctor or health care provider immediately.
Store between 2 and 30 degrees C (36 and 86 degrees F) away from moisture and heat. Keep the container tightly closed. Throw away any unused medicine after the expiration date. Keep out of the reach of children.
Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC). What a cardiologist needs to know about patients with human immunodeficiency virus infection. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Buy combivir. What you need to know about Combivir. Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.
Be careful with Generic Combivir while you are pregnant or have nurseling. Generic Combivir can pass in breast milk and harm your baby.
Do not use Generic Combivir if you are allergic to Generic Combivir components.
Do not use Generic Combivir if you are taking stavudine, zalcitabine, or other medicines containing lamivudine or zidovudine.
Do not use Generic Combivir if you have severe kidney problems, decreased liver function, abnormal liver function tests, or high levels of lactic acid in the blood (lactic acidosis).
Be careful with Generic Combivir if you weigh less than 66 lbs (30 kg) .
Be careful with Generic Combivir if you have a history of liver problems (eg, abnormal liver function tests, hepatitis B infection) or lactic acidosis, kidney problems, a bone marrow disorder, pancreas problems, abnormal blood cell counts, or nerve or muscle problems.
Be careful with Generic Combivir if you are significantly overweight.
Be careful with Generic Combivir if you take interferon alfa or ribavirin because serious liver problems may occur; stavudine because its effectiveness may be decreased by Generic Combivir; clarithromycin, doxorubicin, rifampin, or zalcitabine because they may decrease Generic Combivir 's effectiveness; acetaminophen, ganciclovir, ibuprofen, methadone, probenecid, trimethoprim/sulfamethoxazole, valproic acid, vancomycin, or zalcitabine because they may increase the risk of Generic Combivir 's side effects or toxic effects.
Do not stop taking it suddenly.
Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. Continuous wavelet transforms for the simultaneous quantitative analysis and dissolution testing of lamivudine-zidovudine tablets. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Thyrotoxic periodic paralysis in a Polynesian male following highly active antiretroviral therapy for HIV infection.
buy combivir online
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. New ways to take old drugs. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral Non-adherence When Talking to Patients? In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.
where to buy combivir
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Continuous wavelet transforms for the simultaneous quantitative analysis and dissolution testing of lamivudine-zidovudine tablets. What you need to know about Combivir. Thyrotoxic periodic paralysis in a Polynesian male following highly active antiretroviral therapy for HIV infection. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity. Response to first line HAART using CD4 cell counts experience in a university hospital in Kingston.
|Target Point||Shipping Method||Tracking||Delivery Time||Price|
|Not trackable||14-21 business days||USD 20.00 per order|
|Trackable, where available||5-9 business days||USD 30.00 per order|
Delivery time is:
no signature is required on delivery.
EMS - 5-9 business days, prices - USD 30.00, signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.
This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).